Early Assessment of Colorectal Cancer by Quantifying Circulating Tumor Cells in Peripheral Blood: ECT2 in Diagnosis of Colorectal Cancer.
Early Assessment of Colorectal Cancer by Quantifying Circulating Tumor Cells in Peripheral Blood: ECT2 in Diagnosis of Colorectal Cancer.
复制标题
DOI：
10.3390/ijms18040743
复制
发表时间：
2017-03-31
影响因子：
5.6
通讯作者：
Yeh KT
中科院分区：
文献类型：
--
作者：
Chen CJ;Sung WW;Chen HC;Chern YJ;Hsu HT;Lin YM;Lin SH;Peck K;Yeh KT
外周血中的循环肿瘤细胞（CTC）是不同癌症类型患者预后不良的指标。然而，大多数用于检测CTC的可用技术显示出低灵敏度和特异性。因此，我们试图找到一种替代的标记物的CTC的结直肠癌。我们直接从90名结直肠癌患者和151名健康供体的1.5 mL外周血中提取CTC的RNA，并通过巢式实时定量聚合酶链反应（PCR）筛选这些样品的候选标记基因。从从微阵列分析的公共数据库中选择的基因中，我们成功地鉴定了上皮细胞转化序列2癌基因（ECT 2）作为表现出高差异表达率（p < 0.01）的基因。ECT 2显示出良好的灵敏度和特异性，曲线下面积（AUC）值为0.821。该标记基因在血清癌胚抗原（CEA）浓度低于5 ng/mL诊断阈值的患者中也具有较高的检出率。因此，ECT 2的表达可以作为一种替代测量方法，可以弥补目前CEA检测在结直肠癌患者诊断和监测中的不足。
Circulating tumor cells (CTCs) in peripheral blood is an indication of poor prognosis for patients with different cancer types. However, most of the available technologies for detecting CTCs show low sensitivity and specificity. Therefore, we attempted to find an alternative marker for CTCs of colorectal cancer. We have directly extracted RNA from CTCs contained in 1.5 mL peripheral blood from 90 colorectal cancer patients and 151 healthy donors, and screened these samples for candidate marker genes by nested real-time quantitative polymerase chain reaction (PCR). From genes selected from a public database of microarray analyses, we successfully identified epithelial cell transforming sequence 2 oncogene (ECT2) as a gene that exhibits high differential expression ratios (p < 0.01). ECT2 displays good sensitivity and specificity, with an area under the curve (AUC) value of 0.821. This marker gene also has a high detection rate in patients with serum carcinoembryonic antigen (CEA) concentrations below the diagnostic threshold of 5 ng/mL. The expression of ECT2 can therefore serve as an alternative measurement that can compensate for the inadequacy of the current CEA test in the diagnosis and monitoring of colorectal cancer patients.